-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Medline, Lowers Price Target to $46

Benzinga·08/12/2026 14:39:01
Listen to the news
JP Morgan analyst Lisa Gill maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $53 to $46.